Non-Invasive Prenatal Test (NIPT) uses a small blood sample from the mother and analyses DNA from the placenta to screen for genetic conditions which could affect the baby’s health.
The test can be performed as early as 10 weeks gestation and has a >99% accuracy for detecting Down syndrome. Furthermore, NIPT is the most accurate screening test for detecting chromosomal aneuploidies including Trisomy 13, 18 & 21. The test can also determine the gender of the baby.
Over a decade of oncology genomic research revealed that cancer can be grouped into hereditary cancer and tumour arising from somatic genetic aberrations, where hereditary cancer accounts for approximately 5-10% of all cancers. Genetic mutations causing an increased risk of cancer can be identified and used to direct an appropriate strategy to minimise and manage those risks. Such identification of a causative mutation can also lead to cascade testing, where other family members can be tested to see whether they carry the same mutation. Our hereditary cancer screening provides clinicians the flexibility to choose which genetic panels to analyze, ensuring that accurate diagnosis, screening and optimal patient management can be achieved.
While on the other hand, our tumour genetic profiling can provide clinically actionable information for patient management including prognostic indications, treatment options, responsiveness to therapy and the availability of clinical trials.
Looking at a collective of clinically relevant genes in the human genome has proven to be an effective way of finding answers to the cause of health conditions of medical concern, be it common or rare. It is also a quicker and more cost-effective diagnosis due to the comprehensive coverage of the genes analysed which will guide clinicians and genetic counselors in patient management. Our test menu covers a wide range of medical disciplines including congenital anomalies, hematology, nephrology, cardiology, neurology, endocrinology, gastroenterology, pulmonology, vascular disorders and more.
Pharmacogenomics is the science of how a patient's genetic makeup influences the way they respond to medications. With pharmacogenomics, clinicians can tailor-make medication plans specifically for their patients based on their genetic profile. This in turn, may prevent potentially dangerous adverse drug reactions.
Our translational genomics laboratory is built by scientists, for scientists alike. We believe a multi-omics approach is going to be the powerhouse of new discovery. One such area is spatialomics, where the genomics/proteomics of cells and tissues are being investigated simultaneously in their microenvironment. Being the certified service provider of NanoString GeoMx® Digital Spatial Profiler, we are proud to bring you the opportunity to perform gene expression analysis in a near single cell-level on FFPE samples. This technology has the power to help researchers pinpoint novel factors and reveal pathways in the tumour microenvironment that is affecting cancer treatment. With our in-house pathologist service, we can provide diagnostic-grade accuracy for immuno-oncology research studies in the field of precision medicine.
